Roquefort Therapeutics PLC Publication of New Research
January 10 2022 - 3:00AM
RNS Non-Regulatory
TIDMROQ
Roquefort Therapeutics PLC
10 January 2022
10 January 2022
Roquefort Therapeutics plc
("Roquefort Therapeutics" or the "Company")
Publication of New Research
Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech
company focused on early-stage opportunities in the biotechnology
sector, is pleased to inform shareholders that a new research note
on the Company has recently been published by Pitt Street
Research.
The research can be found on the Company's website via the link
below:
https://www.roquefortinvest.com/research-reports
ENDS
Enquiries:
Roquefort Therapeutics plc
+44 (0)20 3290
Stephen West (Chairman) 9339
Buchanan (Public Relations)
Ben Romney / Jamie Hooper / George
Beale
+44 (0)20 7466
Optiva Securities Limited (Broker) 5000
+44 (0)20 3411
Christian Dennis 1881
For further information on Roquefort Therapeutics, please visit
www.roquefortinvest.com and @roquefortinvest on Twitter.
LEI: 254900P4SISIWOR9RH34
About Roquefort Therapeutics
Roquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech
company developing products through the pre-clinical phase prior to
partnering or selling to big pharma. The Company's wholly owned
subsidiary, Lyramid Pty Ltd ("Lyramid"), is a pre-clinical biotech
company focused on developing first in class Midkine inhibiting RNA
therapeutics drugs for the treatment of cancer, chronic
inflammatory, autoimmune disorder and COVID-19. Recent progress
within mRNA therapeutics has led to a reduction in drug development
timelines and costs, increasing the chance of early value
creation.
Through extensive research resulting in validation through
publication in over 1,000 scientific journals, Lyramid has
identified the potential to exploit the broad therapeutic potential
of Midkine for a number of clinical indications of unmet needs.
Lyramid holds the largest global IP portfolio on Midkine. The
Midkine blocking drug development markets have significant global
market potential (in the multi-billion dollars). Lyramid's
pre-clinical programme is currently underway with an initial focus
on cancer (including immunotherapy resistance) and COVID-19.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange s
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAFZGGMNNLGZZM
(END) Dow Jones Newswires
January 10, 2022 03:00 ET (08:00 GMT)
Roquefort Therapeutics (LSE:ROQ)
Historical Stock Chart
From May 2024 to Jun 2024
Roquefort Therapeutics (LSE:ROQ)
Historical Stock Chart
From Jun 2023 to Jun 2024